by Tatokoro, M. et al.
Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma.
Cancer Sci. 2011; 1:137-43